SUPN — Supernus Pharmaceuticals Share News
0.000.00%
Last trade - 00:00- $2.30bn
- $1.93bn
- $718.95m
U.S. FDA declines to approve Supernus' drug-device combination for Parkinson's disease
U.S. RESEARCH ROUNDUP-Autozone, Constellation Energy, Sterling Infrastructure
Supernus Pharmaceuticals Inc reports results for the quarter ended in December - Earnings Summary
Brief: Supernus Pharmaceuticals Q4 Revenue USD 46.4 Million Vs. IBES Estimate USD 155 Million
Supernus Pharmaceuticals Inc expected to post earnings of 55 cents a share - Earnings Preview
Brief: Knight Therapeutics Enters Into Exclusive License Agreement With Supernus Pharmaceuticals For Qelbree® (Viloxazine) In Canada
US Consumer group seeks stronger warnings on Botox, similar treatments
Brief: Supernus Pharmaceuticals Q3 Revenue USD 153.9 Million Vs. IBES Estimate USD 143.4 Million
Brief: Bethany L. Sensenig Joins Supernus’ Board Of Directors
Supernus Pharmaceuticals Inc reports results for the quarter ended in June - Earnings Summary
Brief: Supernus Pharmaceuticals posts Q2 revenue USD 135.5 million
Supernus Pharmaceuticals Inc expected to post a loss of 23 cents a share - Earnings Preview
Brief: Supernus Pharmaceuticals Inc Enters Into Settlement And License Agreements With Apotex Inc And Apotex Corp
Supernus Pharmaceuticals Inc reports results for the quarter ended in March - Earnings Summary
Brief: Supernus Announces First Quarter 2023 Financial Results
Brief: Supernus Pharmaceuticals Sees FY revenue USD 580-620 million
Supernus Pharmaceuticals Inc expected to post earnings of 17 cents a share - Earnings Preview
Supernus Pharmaceuticals Inc reports results for the quarter ended in December - Earnings Summary
Brief: Supernus Announces Fourth Quarter And Full Year 2022 Financial Results